RxDoctor Payments Data

Jennifer Wagy, NP

Primary Care · Casper, WYNPI 1861042392

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Lundbeck LLC at 25.0% of the total.

$558in general payments, 2019–2025

Across 28 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$139
  • GSK$89
  • Lilly USA, LLC$70
  • AbbVie$52
  • AstraZeneca$44
  • Edwards Lifesciences$41
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lundbeck LLC7$139
GSK5$89
Lilly USA, LLC4$70
AbbVie2$52
AstraZeneca3$44
Edwards Lifesciences1$41
Viatris Specialty LLC1$28
Novartis1$24
Sanofi Pasteur Inc.1$24
Novo Nordisk1$17
Digestive Care, Inc.1$16
Amgen1$15

How this compares

$558 in reported general payments places this provider in the 85th percentile of 24 primary care providers in Wyoming.

See all primary care providers in Wyoming

Medicare billing

Part B allowed, 2024
$42,734
Medicare patients
269
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$12,340
Levothyroxine Sodium90$872
SynthroidLevothyroxine Sodium14$838
Duloxetine Hcl22$572
Gabapentin26$567
Atorvastatin Calcium74$561
Omeprazole17$446
Rosuvastatin Calcium28$392
Tamsulosin Hcl11$377
Pantoprazole Sodium22$359
Lisinopril41$278
Ondansetron OdtOndansetron22$241
Losartan Potassium35$238
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$206
Simvastatin19$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$70$12,34011 claims
AbbVieSynthroid$52$83814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 24 primary care providers in Wyoming.

Other primary care in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →